PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33574568-0	2021	SL010110, a lead compound, inhibits gluconeogenesis via SIRT2-p300-mediated PEPCK1 degradation and improves glucose homeostasis in diabetic mice.	sl010110	0-8	sirtuin 2	Mus musculus	56-61	
33574568-12	2021	This study reveals that SL010110 is a lead compound with a distinct mechanism of suppressing gluconeogenesis via SIRT2-p300-mediated PEPCK1 degradation and potent anti-hyperglycemic activity for the treatment of T2D.	sl010110	24-32	sirtuin 2	Mus musculus	113-118	
33574568-8	2021	SL010110 decreased NAD+/NADH ratio, inhibited SIRT2 activity, and further promoted p300 acetyltransferase activation and PEPCK1 acetylation.	sl010110	0-8	sirtuin 2	Mus musculus	46-51	
33574568-9	2021	These effects were blocked by NMN, an NAD+ precursor, suggested that SL010110 inhibited gluconeogenesis by inhibiting SIRT2, activating p300, and subsequently promoting PEPCK1 acetylation.	sl010110	69-77	sirtuin 2	Mus musculus	118-123	
33574568-10	2021	In type 2 diabetic ob/ob mice, single oral dose of SL010110 (100 mg/kg) suppressed gluconeogenesis accompanied by the suppressed hepatic SIRT2 activity, increased p300 activity, enhanced PEPCK1 acetylation and degradation.	sl010110	51-59	sirtuin 2	Mus musculus	137-142